Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer
10.21.2008 Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer
SAN DIEGO – October 21, 2008 -- Althea Technologies, Inc., a leading provider of innovative services and technologies for pharmaceutical development and manufacturing, announced today that Shabbir Anik, Ph.D., will join the company as its President and Chief Executive Officer. Dr. Anik, the former President of Pharmaceutical Development Services (PDS) at Patheon, Inc., will lead Althea’s expansion of its product development, clinical trial and commercial manufacturing services.
“We are delighted to welcome Dr. Anik to Althea and feel that his background and expertise is a wonderful match for the company,” stated Dr. Magda Marquet, Co-Chair of Althea Technologies. “He is a rare blend of scientist, manager and leader, and we are excited about Althea’s continued success with Shabbir at the helm. Althea has emerged as a leader in speeding biopharmaceuticals and exciting new therapeutics to clinical evaluation. That position has been recently enhanced with our addition of commercial manufacturing services. As we continue to grow to serve our clients, Shabbir’s experience in manufacturing, his understanding of the critical interplay of services in bringing a product to commercial success, and his ability to manage these activities across the globe will be invaluable to Althea.”
Dr. Anik holds a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin and an MBA from Santa Clara University. He began his career at Syntex, serving in positions of increasing responsibility leading to the position of Vice President and Program Director. He also served as Senior Director of Pharmaceutical Development and Operations for the biotechnology company Neurex, before most recently joining Patheon, Inc., where he was responsible for building and managing Patheon’s global PDS business.
“I can’t think of a more powerful pairing than the combination of Shabbir’s leadership and Althea’s team, to continue our company’s growth as the most trusted outsource manufacturer for those developing tomorrow’s successful therapeutics. This will allow Althea to drive confidently forward, to grow into new areas while seeking to raise the bar as a leading service provider to the industry,” stated Dr. François Ferré, Co-Chair of Althea.
“I am delighted to be joining Althea Technologies at this very exciting stage in its growth, and to help build on the foundation established through the dedication and hard work of the Althea team. Althea has a solid reputation for its expertise in providing development and manufacturing services, and with the recent introduction of its state-of-the-art commercial manufacturing facilities, Althea now provides an integrated approach for exciting new products from early development to launch. I am convinced that we can continue to deliver the gold standard of performance in the years ahead and I look forward to contributing my experience to make Althea the partner of choice,” said Dr. Anik.
Dr. Anik will join the firm effective November 15, 2008. Dr. Magda Marquet and Dr. François Ferré, the company’s co-founders and former Co-CEO’s will continue to serve Althea as Co-Chairmen of the Board of Directors.
About Althea Technologies, Inc.
Althea Technologies, a leading San Diego-based biologics and pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea’s services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling.